Takeda Pharmaceutical and Ovid Therapeutics, a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, has announced the formation of a global collaboration focused on the clinical development and commercialization of Takeda’s investigational new drug TAK-935, a novel, potent and highly selective CH24H inhibitor, in rare pediatric epilepsies. TAK-935 has successfully completed several phase I clinical studies under Takeda’s leadership and will be moving into phase Ib/IIa clinical studies in rare epileptic encephalopathies where patients continue to suffer from significant unmet medical needs.
PharmAthene, Altimmune merge
WuXi AppTec acquires HD Biosciences
Portable Genomics, CFTechnology.org partner
The Pulse on Technology by Elisa Cascade
EDC, RBM, SSO, etc.—These three-letter acronyms related to technology are enough to make your head spin. Everyone’s talking about the latest site-facing technology and how it could improve clinical trial operations efficiency, but I thought I would start off the new year (and the new Pulse on Technology column) by setting the record straight on current technology usage by global sites. This will also set us up for future deep-dives into individual clinical trial technologies!